Adult Immuno-oncology: Using Past Failures to Inform the Future

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2020 May 12

PMID 32391559

Citations 16

Authors

Maryam Rahman

W Gregory Sawyer

Scott Lindhorst

Loic P Deleyrolle

Jeffrey K Harrison

Aida Karachi

Farhad Dastmalchi

Joseph Flores-Toro

Duane A Mitchell

Michael Lim

Mark R Gilbert

David A Reardon

Affiliations

Soon will be listed here.

Abstract

In oncology, "immunotherapy" is a broad term encompassing multiple means of utilizing the patient's immune system to combat malignancy. Prominent among these are immune checkpoint inhibitors, cellular therapies including chimeric antigen receptor T-cell therapy, vaccines, and oncolytic viruses. Immunotherapy for glioblastoma (GBM) has had mixed results in early trials. In this context, the past, present, and future of immune oncology for the treatment of GBM was discussed by clinical, research, and thought leaders as well as patient advocates at the first annual Remission Summit in 2019. The goal was to use current knowledge (published and unpublished) to identify possible causes of treatment failures and the best strategies to advance immunotherapy as a treatment modality for patients with GBM. The discussion focuses on past failures, current limitations, failure analyses, and proposed best practices moving forward.

Citing Articles

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells.

Li G, Yang H, Ke T, Tan N, Du X, Duan X J Transl Med. 2025; 23(1):164.

PMID: 39920704 PMC: 11806791. DOI: 10.1186/s12967-025-06194-y.

Sphingosine kinase 1 promotes M2 macrophage infiltration and enhances glioma cell migration via the JAK2/STAT3 pathway.

Song Z, Zhao Z, Liu X, Song Y, Zhu S, Jia Z Sci Rep. 2025; 15(1):4152.

PMID: 39900970 PMC: 11790894. DOI: 10.1038/s41598-025-88328-2.

PTEN loss in glioma cell lines leads to increased extracellular vesicle biogenesis and PD-L1 cargo in a PI3K-dependent manner.

Sanchez J, Pierpont T, Argueta-Zamora D, Wilson K, August A, Cerione R J Biol Chem. 2024; 301(2):108143.

PMID: 39732171 PMC: 11791317. DOI: 10.1016/j.jbc.2024.108143.

The abscopal effects of sonodynamic therapy in cancer.

Collins V, Hutton D, Hossain-Ibrahim K, Joseph J, Banerjee S Br J Cancer. 2024; 132(5):409-420.

PMID: 39537767 PMC: 11876350. DOI: 10.1038/s41416-024-02898-y.

Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade.

von Roemeling C, Patel J, Carpenter S, Yegorov O, Yang C, Bhatia A Nat Commun. 2024; 15(1):5871.

PMID: 38997283 PMC: 11245621. DOI: 10.1038/s41467-024-49989-1.

References

Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y . Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014; 110(10):2560-8. PMC: 4021514. DOI: 10.1038/bjc.2014.162. View

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

Fasterius E, Uhlen M, Szigyarto C . Single-cell RNA-seq variant analysis for exploration of genetic heterogeneity in cancer. Sci Rep. 2019; 9(1):9524. PMC: 6606766. DOI: 10.1038/s41598-019-45934-1. View

Sharma S, Yang S, Zhu L, Reckamp K, Gardner B, Baratelli F . Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005; 65(12):5211-20. DOI: 10.1158/0008-5472.CAN-05-0141. View

Badie B, Schartner J . Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery. 2000; 46(4):957-61; discussion 961-2. DOI: 10.1097/00006123-200004000-00035. View

Heimberger A, Learn C, Archer G, McLendon R, Chewning T, Tuck F . Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res. 2002; 8(11):3496-502. View

Morford L, ELLIOTT L, Carlson S, Brooks W, Roszman T . T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol. 1997; 159(9):4415-25. View

Su E, Lin J, Kane L . TIM-1 and TIM-3 proteins in immune regulation. Cytokine. 2008; 44(1):9-13. PMC: 2574986. DOI: 10.1016/j.cyto.2008.06.013. View

Brat D, Castellano-Sanchez A, Hunter S, Pecot M, Cohen C, Hammond E . Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 2004; 64(3):920-7. DOI: 10.1158/0008-5472.can-03-2073. View

10.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D . HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017; 3(8):1094-1101. PMC: 5747970. DOI: 10.1001/jamaoncol.2017.0184. View

11.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

12.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

13.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

14.

Van Allen E, Miao D, Schilling B, Shukla S, Blank C, Zimmer L . Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207-211. PMC: 5054517. DOI: 10.1126/science.aad0095. View

15.

Brown C, Alizadeh D, Starr R, Weng L, Wagner J, Naranjo A . Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016; 375(26):2561-9. PMC: 5390684. DOI: 10.1056/NEJMoa1610497. View

16.

Liau L, Jensen E, Kremen T, Odesa S, Sykes S, Soung M . Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res. 2002; 62(8):2287-93. View

17.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

18.

Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber S . T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018; 24(17):4175-4186. PMC: 6081269. DOI: 10.1158/1078-0432.CCR-17-1846. View

19.

Liebert M, Wahl R, Lawless G, McKeever P, TAREN J, BEIERWALTES W . Direct stereotactic intracerebral injection of monoclonal antibodies and their fragments: a potential approach to brain tumor immunotherapy. Am J Physiol Imaging. 1990; 5(2):55-9. View

20.

Schaer D, Murphy J, Wolchok J . Modulation of GITR for cancer immunotherapy. Curr Opin Immunol. 2012; 24(2):217-24. PMC: 3413251. DOI: 10.1016/j.coi.2011.12.011. View